Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways

Journal of Nutritional Biochemistry

Volumn 41, Issue , 2017, Pages 124-136

  Granato, Marisa ^a   Rizzello, Celeste ^a   Montani, Maria Saveria Gilardini ^a   Cuomo, Laura ^b   Vitillo, Marina ^b   Santarelli, Roberta ^a   Gonnella, Roberta ^a   D'Orazi, Gabriella ^c,d   Faggioni, Alberto ^a   Cirone, Mara ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Il 6; KSHV; mTOR PI3K AKT; PEL; Quercetin; STAT3

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BORTEZOMIB; CALRETICULIN; CYCLIN D1; DACTOLISIB; FLICE INHIBITORY PROTEIN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUERCETIN; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; INTERLEUKIN DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEASOME INHIBITOR; STAT3 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; B CELL LYMPHOMA; CARCINOGENESIS; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPHOMA CELL; PRIMARY EFFUSION LYMPHOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR IMMUNOGENICITY; UPREGULATION; AGONISTS; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; DRUG RECEPTOR BINDING; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOPHAGY; B-LYMPHOCYTES; BORTEZOMIB; CELL LINE, TUMOR; CELLS, CULTURED; DOWN-REGULATION; DRUG AGONISM; HUMANS; INTERLEUKINS; LYMPHOMA, PRIMARY EFFUSION; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 85009104947     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2016.12.011     Document Type: Article

References (67)

1. [1] Ganem, D., KSHV-induced oncogenesis. Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., (eds.) Human Herpesviruses: biology, therapy, and Immunoprophylaxis, Cambridge, 2007.
2. [2] Bhatt, A.P., Damania, B., AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV. Front Immunol, 3, 2012, 401.
3. [3] Aoki, Y., Feldman, G.M., Tosato, G., Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101:4 (2003), 1535–1542.
4. [4] Fujimuro, M., Wu, F.Y., ApRhys, C., Kajumbula, H., Young, D.B., Hayward, G.S., et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 9:3 (2003), 300–306.
5. [5] Granato, M., Santarelli, R., Gonnella, R., Farina, A., Trivedi, P., Faggioni, A., et al. Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and future. Biomed Res Int, 2015, 2015, 104912.
6. [6] Granato, M., Santarelli, R., Lotti, L.V., Di Renzo, L., Gonnella, R., Garufi, A., et al. JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. PLoS One, 8(9), 2013, e75965.
7. [7] Granato, M., Chiozzi, B., Filardi, M.R., Lotti, L.V., Di Renzo, L., Faggioni, A., et al. Tyrosine kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and mcl-1 in PEL cells. Cancer Lett 366:2 (2015), 191–197.
8. [8] Punjabi, A.S., Carroll, P.A., Chen, L., Lagunoff, M., Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol 81:5 (2007), 2449–2458.
9. [9] Jarviluoma, A., Ojala, P.M., Cell signaling pathways engaged by KSHV. Biochim Biophys Acta 1766:1 (2006), 140–158.
10. [10] Gasperini, P., Sakakibara, S., Tosato, G., Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol 84:4 (2008), 994–1000.
11. [11] Aoki, Y., Jones, K.D., Tosato, G., Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. J Hematother Stem Cell Res 9:2 (2000), 137–145.
12. [12] Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M.A., Hall, A., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:11 (2004), 1122–1128.
13. [13] Bhatt, A.P., Bhende, P.M., Sin, S.H., Roy, D., Dittmer, D.P., Damania, B., Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115:22 (2010), 4455–4463.
14. [14] Manach, C., Scalbert, A., Morand, C., Remesy, C., Jimenez, L., Polyphenols: food sources and bioavailability. Am J Clin Nutr 79:5 (2004), 727–747.
15. [15] Bruning, A., Inhibition of mTOR signaling by quercetin in cancer treatment and prevention. Anti Cancer Agents Med Chem 13:7 (2013), 1025–1031.
16. [16] Gilardini Montani, M.S., Granato, M., Cuomo, L., Valia, S., Di Renzo, L., D'Orazi, G., et al. High glucose and hyperglycemic sera from type 2 diabetic patients impair DC differentiation by inducing ROS and activating Wnt/beta-catenin and p38 MAPK. Biochim Biophys Acta 1862:4 (2016), 805–813.
17. [17] Novo, M.C., Osugui, L., dos Reis, V.O., Longo-Maugeri, I.M., Mariano, M., Popi, A.F., Blockage of Wnt/beta-catenin signaling by quercetin reduces survival and proliferation of B-1 cells in vitro. Immunobiology 220:1 (2015), 60–67.
18. [18] Voskas, D., Ling, L.S., Woodgett, J.R., Does GSK-3 provide a shortcut for PI3K activation of Wnt signalling?. F1000 Biol Rep, 2, 2010, 82.
19. [19] Michaud-Levesque, J., Bousquet-Gagnon, N., Beliveau, R., Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res 318:8 (2012), 925–935.
20. [20] Vogt, P.K., Hart, J.R., PI3K and STAT3: a new alliance. Cancer Discov 1:6 (2011), 481–486.
21. [21] Yokogami, K., Wakisaka, S., Avruch, J., Reeves, S.A., Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10:1 (2000), 47–50.
22. [22] Chen, W., Padilla, M.T., Xu, X., Desai, D., Krzeminski, J., Amin, S., et al. Quercetin inhibits multiple pathways involved in interleukin 6 secretion from human lung fibroblasts and activity in bronchial epithelial cell transformation induced by benzo[a]pyrene diol epoxide. Mol Carcinog 55:11 (2016), 1858–1866.
23. [23] Russo, G.L., Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S., Iannitti, R., et al. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat Res 159 (2014), 185–205.
24. [24] Uddin, S., Hussain, A.R., Manogaran, P.S., Al-Hussein, K., Platanias, L.C., Gutierrez, M.I., et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 24:47 (2005), 7022–7030.
25. [25] Santarelli, R., Gonnella, R., Di Giovenale, G., Cuomo, L., Capobianchi, A., Granato, M., et al. STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells. Sci Rep, 4, 2014, 4241.
26. [26] Shanware, N.P., Bray, K., Abraham, R.T., The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol 53 (2013), 89–106.
27. [27] Jonchere, B., Belanger, A., Guette, C., Barre, B., Coqueret, O., STAT3 as a new autophagy regulator. JAKSTAT, 2(3), 2013, e24353.
28. [28] Baehrecke, E.H., Autophagy: dual roles in life and death?. Nat Rev Mol Cell Biol 6:6 (2005), 505–510.
29. [29] Bhende, P.M., Park, S.I., Lim, M.S., Dittmer, D.P., Damania, B., The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 24:10 (2010), 1781–1784.
30. [30] Granato, M., Santarelli, R., Filardi, M., Gonnella, R., Farina, A., Torrisi, M.R., et al. The activation of KSHV lytic cycle blocks autophagy in PEL cells. Autophagy 11:11 (2015), 1978–1986.
31. [31] Fimia, G.M., Stoykova, A., Romagnoli, A., Giunta, L., Di Bartolomeo, S., Nardacci, R., et al. Ambra1 regulates autophagy and development of the nervous system. Nature 447:7148 (2007), 1121–1125.
32. [32] Sander, G., Konrad, A., Thurau, M., Wies, E., Leubert, R., Kremmer, E., et al. Intracellular localization map of human herpesvirus 8 proteins. J Virol 82:4 (2008), 1908–1922.
33. [33] Frajese, G.V., Benvenuto, M., Fantini, M., Ambrosin, E., Sacchetti, P., Masuelli, L., et al. Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines in vitro. Oncol Lett 11:6 (2016), 4224–4234.
34. [34] Blaecke, A., Delneste, Y., Herbault, N., Jeannin, P., Bonnefoy, J.Y., Beck, A., et al. Measurement of nuclear factor-kappa B translocation on lipopolysaccharide-activated human dendritic cells by confocal microscopy and flow cytometry. Cytometry 48:2 (2002), 71–79.
35. [35] Chaitanya, G.V., Steven, A.J., Babu, P.P., PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal, 8, 2010, 31.
36. [36] Gulati, N., Laudet, B., Zohrabian, V.M., Murali, R., Jhanwar-Uniyal, M., The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res 26:2A (2006), 1177–1181.
37. [37] Cross, D.A., Alessi, D.R., Vandenheede, J.R., McDowell, H.E., Hundal, H.S., Cohen, P., The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J 303:Pt 1 (1994), 21–26.
38. [38] Sin, S.H., Roy, D., Wang, L., Staudt, M.R., Fakhari, F.D., Patel, D.D., et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 109:5 (2007), 2165–2173.
39. [39] Jones, K.D., Aoki, Y., Chang, Y., Moore, P.S., Yarchoan, R., Tosato, G., Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 94:8 (1999), 2871–2879.
40. [40] Cirone, M., Di Renzo, L., Lotti, L.V., Conte, V., Trivedi, P., Santarelli, R., et al. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One, 7(3), 2012, e31732.
41. [41] Aoki, Y., Tosato, G., Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders. Expert Rev Anti-Infect Ther 2:2 (2004), 213–225.
42. [42] Murray, P.J., The JAK–STAT signaling pathway: input and output integration. J Immunol 178:5 (2007), 2623–2629.
43. [43] Yan, S., Zhou, C., Zhang, W., Zhang, G., Zhao, X., Yang, S., et al. Beta-catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett 271:1 (2008), 85–97.
44. [44] Ma, H., Nguyen, C., Lee, K.S., Kahn, M., Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24:22 (2005), 3619–3631.
45. [45] Shan, B.E., Wang, M.X., Li, R.Q., Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Investig 27:6 (2009), 604–612.
46. [46] Belanger, C., Gravel, A., Tomoiu, A., Janelle, M.E., Gosselin, J., Tremblay, M.J., et al. Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. J Hum Virol 4:2 (2001), 62–73.
47. [47] Guasparri, I., Keller, S.A., Cesarman, E., KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 199:7 (2004), 993–1003.
48. [48] Keller, S.A., Hernandez-Hopkins, D., Vider, J., Ponomarev, V., Hyjek, E., Schattner, E.J., et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 107:8 (2006), 3295–3302.
49. [49] Gantt, S., Casper, C., Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 24:4 (2011), 295–301.
50. [50] Granato, M., Gilardini Montani, M.S., Filardi, M., Faggioni, A., Cirone, M., Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression. Oncotarget 6:30 (2015), 29543–29554.
51. [51] Yu, S., Shen, G., Khor, T.O., Kim, J.H., Kong, A.N., Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 7:9 (2008), 2609–2620.
52. [52] Lee, J.S., Li, Q., Lee, J.Y., Lee, S.H., Jeong, J.H., Lee, H.R., et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol 11:11 (2009), 1355–1362.
53. [53] Matta, H., Chaudhary, P.M., The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 4:1 (2005), 77–82.
54. [54] Thakker, S., Purushothaman, P., Gupta, N., Challa, S., Cai, Q., Verma, S.C., Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits major histocompatibility complex class II expression by disrupting Enhanceosome assembly through binding with the regulatory factor X complex. J Virol 89:10 (2015), 5536–5556.
55. [55] Ishido, S., Wang, C., Lee, B.S., Cohen, G.B., Jung, J.U., Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 74:11 (2000), 5300–5309.
56. [56] Schmidt, K., Wies, E., Neipel, F., Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression. J Virol 85:9 (2011), 4530–4537.
57. [57] Areste, C., Blackbourn, D.J., Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. Trends Microbiol 17:3 (2009), 119–129.
58. [58] Lodoen, M.B., Lanier, L.L., Viral modulation of NK cell immunity. Nat Rev Microbiol 3:1 (2005), 59–69.
59. [59] Garg, A.D., Dudek-Peric, A.M., Romano, E., Agostinis, P., Immunogenic cell death. Int J Dev Biol 59:1–3 (2015), 131–140.
60. [60] Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L., Immunogenic cell death in cancer therapy. Annu Rev Immunol 31 (2013), 51–72.
61. [61] Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.L., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:1 (2007), 54–61.
62. [62] Middleton, E. Jr., Kandaswami, C., Theoharides, T.C., The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:4 (2000), 673–751.
63. [63] Long, H.M., Leese, A.M., Chagoury, O.L., Connerty, S.R., Quarcoopome, J., Quinn, L.L., et al. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J Immunol 187:1 (2011), 92–101.
64. [64] Cao, H.H., Tse, A.K., Kwan, H.Y., Yu, H., Cheng, C.Y., Su, T., et al. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol 87:3 (2014), 424–434.
65. [65] Bubman, D., Guasparri, I., Cesarman, E., Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 26:34 (2007), 4979–4986.
66. [66] Wang, K., Liu, R., Li, J., Mao, J., Lei, Y., Wu, J., et al. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt–mTOR- and hypoxia-induced factor 1alpha-mediated signaling. Autophagy 7:9 (2011), 966–978.
67. [67] Hasima, N., Ozpolat, B., Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis, 5, 2014, e1509.